Hepatitis C in Developing Countries: Current and Future Challenges explores the current state of HCV in several countries, including Africa, Asia and South America. It maintains a dedicated focus on the epidemiology, clinical patterns, virologic diversity, coinfections, natural history and progression, complications, and response to standard of care (SOC) pegylated interferon and ribavirin therapy of HCV with recommendations specific to middle and low income countries. Readers will find detailed information on the burden of HCV infection from a global health and economic perspective, along with data from multicenter trials on DAAs that have enrolled patients infected with HCV non-genotype 1. Features coverage on the prevention of, or inhibition of, liver fibrosis, cirrhosis, and hepatocellular carcinoma Presents data from trials on patients with diverse ethnic backgrounds and those infected with genotypes 3, 4, 5, 6 Addresses the epidemiology, modes of transmission, socio-political aspects, genotypes, and co-infections of Hepatitis C
Therefore, this book has been created by distinguished faculties from around the world to address the progress in our understanding of HCV infection and to review new treatment options, limitations, and accessibility of new therapeutic ...
Collected in this volume are the papers from the symposium, providing a valuable resource for hepatologists, gastroenterologists, and others working to understand and treat viral hepatitis.
Incidence of drug interactions identified by clinical pharmacists in veterans initiating treatment for chronic Hepatitis C infection. Annals of Pharmacotherapy 2018; 52(8):763–768. 2. Smolders EJ, Berden F, de Kanter C et al.
The book presents ways to reduce the numbers of new HBV and HCV infections and the morbidity and mortality related to chronic viral hepatitis.
These are the first WHO guidelines on testing for chronic HBV and HCV infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection.
Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis.
This book presents up-to-date, practically oriented information on major topics in chronic hepatitis C. The coverage encompasses epidemiology; diagnosis, including molecular methods; treatment and challenges; and the management of co ...
This book provides useful informations about diagnostic, prevalence and drug discovery initiative against HCV genotype-3a (HCV-3a), the most prevalent genotype in developing world, particularly in South Asia including Pakistan.
In this volume, world-leading experts in the field of HCV research have compiled the most recent scientific advances to provide a comprehensive and very timely overview of the various facets of HCV.
In addition, an outstanding chapter on the skin involvement during viral hepatitis and the tools to manage them during triple therapy is included in the book.